These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 38572639)

  • 21. Mechanistic Phase II Clinical Trial of Metformin in Pulmonary Arterial Hypertension.
    Brittain EL; Niswender K; Agrawal V; Chen X; Fan R; Pugh ME; Rice TW; Robbins IM; Song H; Thompson C; Ye F; Yu C; Zhu H; West J; Newman JH; Hemnes AR
    J Am Heart Assoc; 2020 Nov; 9(22):e018349. PubMed ID: 33167773
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk Reduction and Right Heart Reverse Remodeling by Upfront Triple Combination Therapy in Pulmonary Arterial Hypertension.
    D'Alto M; Badagliacca R; Argiento P; Romeo E; Farro A; Papa S; Sarubbi B; Russo MG; Vizza CD; Golino P; Naeije R
    Chest; 2020 Feb; 157(2):376-383. PubMed ID: 31563498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension.
    Humbert M; McLaughlin V; Gibbs JSR; Gomberg-Maitland M; Hoeper MM; Preston IR; Souza R; Waxman AB; Ghofrani HA; Escribano Subias P; Feldman J; Meyer G; Montani D; Olsson KM; Manimaran S; de Oliveira Pena J; Badesch DB
    Eur Respir J; 2023 Jan; 61(1):. PubMed ID: 36041750
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of echocardiographic variables of right ventricular function with exercise capacity after bosentan treatment in patients with pulmonary arterial hypertension: Results from a multicenter, prospective, cohort study.
    Kim H; Bae Lee J; Park JH; Yoo BS; Son JW; Yang DH; Lee BR
    J Clin Ultrasound; 2017 Jan; 45(1):28-34. PubMed ID: 27619758
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of right ventricular reserve on exercise capacity and survival in patients with pulmonary hypertension.
    Blumberg FC; Arzt M; Lange T; Schroll S; Pfeifer M; Wensel R
    Eur J Heart Fail; 2013 Jul; 15(7):771-5. PubMed ID: 23507788
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impaired Cardiac Reserve and Abnormal Vascular Load Limit Exercise Capacity in Chronic Thromboembolic Disease.
    Claeys M; Claessen G; La Gerche A; Petit T; Belge C; Meyns B; Bogaert J; Willems R; Claus P; Delcroix M
    JACC Cardiovasc Imaging; 2019 Aug; 12(8 Pt 1):1444-1456. PubMed ID: 30219401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study.
    Hoeper MM; Barst RJ; Bourge RC; Feldman J; Frost AE; Galié N; Gómez-Sánchez MA; Grimminger F; Grünig E; Hassoun PM; Morrell NW; Peacock AJ; Satoh T; Simonneau G; Tapson VF; Torres F; Lawrence D; Quinn DA; Ghofrani HA
    Circulation; 2013 Mar; 127(10):1128-38. PubMed ID: 23403476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population Health Model Predicting the Long-Term Impact of Sotatercept on Morbidity and Mortality in Patients with Pulmonary Arterial Hypertension (PAH).
    McLaughlin V; Alsumali A; Liu R; Klok R; Martinez EC; Nourhussein I; Bernotas D; Chevure J; Pausch C; De Oliveira Pena J; Lautsch D; Hoeper MM
    Adv Ther; 2024 Jan; 41(1):130-151. PubMed ID: 37851297
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial.
    Jing ZC; Parikh K; Pulido T; Jerjes-Sanchez C; White RJ; Allen R; Torbicki A; Xu KF; Yehle D; Laliberte K; Arneson C; Rubin LJ
    Circulation; 2013 Feb; 127(5):624-33. PubMed ID: 23307827
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.
    Tapson VF; Jing ZC; Xu KF; Pan L; Feldman J; Kiely DG; Kotlyar E; McSwain CS; Laliberte K; Arneson C; Rubin LJ;
    Chest; 2013 Sep; 144(3):952-958. PubMed ID: 23669822
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physical activity in incident patients with pulmonary arterial and chronic thromboembolic hypertension.
    Saxer S; Lichtblau M; Berlier C; Hasler ED; Schwarz EI; Ulrich S
    Lung; 2019 Oct; 197(5):617-625. PubMed ID: 31263960
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exercise cardiac MRI unmasks right ventricular dysfunction in acute hypoxia and chronic pulmonary arterial hypertension.
    Jaijee S; Quinlan M; Tokarczuk P; Clemence M; Howard LSGE; Gibbs JSR; O'Regan DP
    Am J Physiol Heart Circ Physiol; 2018 Oct; 315(4):H950-H957. PubMed ID: 29775415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sotatercept for Pulmonary Arterial Hypertension in the Inpatient Setting.
    Torbic H; Tonelli AR
    J Cardiovasc Pharmacol Ther; 2024; 29():10742484231225310. PubMed ID: 38361351
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of imatinib as add-on therapy on echocardiographic measures of right ventricular function in patients with significant pulmonary arterial hypertension.
    Shah AM; Campbell P; Rocha GQ; Peacock A; Barst RJ; Quinn D; Solomon SD;
    Eur Heart J; 2015 Mar; 36(10):623-32. PubMed ID: 24566799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial.
    Galiè N; Humbert M; Vachiéry JL; Vizza CD; Kneussl M; Manes A; Sitbon O; Torbicki A; Delcroix M; Naeije R; Hoeper M; Chaouat A; Morand S; Besse B; Simonneau G;
    J Am Coll Cardiol; 2002 May; 39(9):1496-502. PubMed ID: 11985913
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sotatercept (Winrevair) for pulmonary arterial hypertension.
    Med Lett Drugs Ther; 2024 May; 66(1702):73-75. PubMed ID: 38696310
    [No Abstract]   [Full Text] [Related]  

  • 37. Exercise physiology in pulmonary hypertension patients with and without congenital heart disease.
    Righini FM; Apostolo A; Heck PB; Farina S; Hager A; Correale M; Badagliacca R; Barbieri S; Sciomer S; Agostoni P
    Eur J Prev Cardiol; 2019 Jan; 26(1):86-93. PubMed ID: 30354746
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease.
    Chauvelot L; Gamondes D; Berthiller J; Nieves A; Renard S; Catella-Chatron J; Ahmad K; Bertoletti L; Camara B; Gomez E; Launay D; Montani D; Mornex JF; Prévot G; Sanchez O; Schott AM; Subtil F; Traclet J; Turquier S; Zeghmar S; Habib G; Reynaud-Gaubert M; Humbert M; Cottin V
    Arthritis Rheumatol; 2021 Feb; 73(2):295-304. PubMed ID: 32892515
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is sotatercept, which traps activins and growth differentiation factors, a new dawn in treating pulmonary arterial hypertension (PAH)?
    Doggrell SA
    Expert Opin Biol Ther; 2023; 23(7):589-593. PubMed ID: 37269300
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Right ventricular dyssynchrony and exercise capacity in idiopathic pulmonary arterial hypertension.
    Badagliacca R; Papa S; Valli G; Pezzuto B; Poscia R; Reali M; Manzi G; Giannetta E; Berardi D; Sciomer S; Palange P; Fedele F; Naeije R; Vizza CD
    Eur Respir J; 2017 Jun; 49(6):. PubMed ID: 28572119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.